by Angus Liu |
May 26, 2020 10:13am
Detailed data from a National Institutes of Health-run study show Gilead Sciences' remdesivir worked best in COVID-19 patients who required oxygen supplementation but were not mechanically ventilated. (Gilead)
Since the National Institutes of Health released preliminary findings backing an FDA emergency authorization of Gilead Sciences’ COVID-19 therapy remdesivir, the medical community has been calling for detailed results to guide treatment practice. And now the data are here.
As the National Institute of Allergy and Infectious Diseases (NIAID) previously outlined, treatment with remdesivir cut recovery time for hospitalized patients by about 30%. Updated two-week death rates leaned further in the Gilead drug's favor at 7.1% versus 11.9% for placebo, though the difference wasn’t statistically significant, according to The New England Journal of Medicine. Previously, the death rates were 8% and 11.6%, respectively.
In a Saturday note to clients, SVB Leerink analyst Geoffrey Porges argued the numeric improvement in mortality, if further validated, “can change sentiment” about COVID-19, and that getting patients to recover faster can alleviate pressure on hospital systems in response to increases in cases.
Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays
Wednesday, May 27, 2020 | 10am ET / 7am PT
A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.
The 1,063-patient study showed remdesivir’s benefits appear greatest for hospitalized patients in the middle of the disease-severity spectrum.
But remdesivir didn’t much help patients with mild or moderate disease, and outcomes for patients on invasive ventilation or extracorporeal membrane oxygenation were nearly the same in both arms of the study.
Overall, the probability of improvement in clinical status was 50% higher among remdesivir patients than in placebo patients.
“It is likely that the treatment benefit from remdesivir will increase in the real world once the lessons of this trial and other studies are incorporated into routine treatment practices,” Porges said.
RELATED: Gilead to start selling remdesivir in coming weeks, expects 'multi-year commercial opportunity'
Still, as Evercore ISI analyst Umer Raffat sees it, the NEJM paper is missing one key data set. “The single most important data disclosure that I was awaiting was this: How does mortality look different in patients that take remdesivir early?” he said. “These early trials on COVID are all about identifying not only whether a drug works, but also when to initiate the drug.”
The new study does separate recovery data for patients randomized within 10 days of symptom onset and those randomized after that point. But it doesn’t specify disease severity in either of those two groups.
Besides, the study, dubbed ACTT-1, stopped early at the recommendation of an independent data monitoring panel. Therefore, only a proportion of patients had completed the trial through day 29, the primary endpoint evaluation date, leaving 132 patients in the remdesivir group and 169 in the placebo group unanalyzed.
Porges acknowledged that, while large, ACTT-1 is just one study. Previously, in a Chinese study that didn’t complete due to low enrollment, researchers only found a numerically faster clinical improvement with remdesivir use compared with placebo in patients who started treatment with symptom duration of 10 days or less.
Gilead itself is running two studies in moderate and severe patients, respectively. In a Friday statement, the company said the moderate-patient trial is expected to read out at the end of this month. Meanwhile, the NIAID has started enrolling patients in the ACTT-2 trial combining remdesivir, an antiviral, with Eli Lilly’s anti-inflammatory JAK inhibitor Olumiant.
Physicians have been waiting anxiously for the detailed results to help direct already limited supply of the drug to those most likely to benefit. Gilead has committed to donating 1.5 million doses of the drug by June, which, depending on the duration of treatment, could cover 150,000 to 250,000 treatment courses. As the only drug to have shown a clear benefit in a large, well-designed clinical trial so far, remdesivir demand is outstripping supply.
After that initial supply runs out, Gilead will pivot to a commercial plan, and all eyes will be on how the biotech plans to charge for the drug. Based on the preliminary ACTT-1 results, drug cost watchdogs at the Institute for Clinical and Economic Review previously pegged $4,460 per course as a fair price for remdesivir.
To share this information copy this link & send https://baliworldnewsviews.blogspot.com/2020/05/bali-reopening-to-tourists-everything.html
Coronavirus Special
Start at $6.00 per Guest
Normal prices are $20-$40. A 70% to 85 % discount.
Azizah & Lawrence with 100 + staff at their head office, in Sanur PT. Bali Luxury Villas
*Prices include a private housekeeper 5.5 days per week. It does not include 11% tax or electricity.
Huge Villas & Estates:
Large Kitchen, Dining & Living Areas:
Fiber Optic Wi-Fi, TV and Telephone:
Award-Winning 24 Hr. Management:
TOP 2% of Hotels In The World:
Limited Villas Book Now to Avoid Disappointment:
Interested parties please contact me. Lawrence, directly at 62-8123814014 Email: lbptbali@gmail.comOr our Rentals Manager: Yanthi at +62 815-5890-0389 or our Reception at PT Bali Luxury Villas at 62-361-284069
To share this information copy this link & send https://baliworldnewsviews.blogspot.com/2020/05/bali-reopening-to-tourists-everything.html
Bali Paradise Beach Estates
The view from this estate
Your own private walkway to the beach, magical walks on the remote beach which runs for 30 km and the sound of exotic birds will make you never want to leave.
Built by Award Winning Bali Developer:
This will keep you in shape and healthy during this difficult time plus provide hours of pleasure for you and your family.
A Gardener and Pool Man is included.
There is only one other estate in this complex at this time.
Beautiful Saba River Only five minutes walk.
Superhosts are experienced, highly rated hosts who are committed to providing great stays for guests. They also have the Hall of Fame award from Tripadvisor.
The Owners Lawrence and Notaris/Spouse Azizah at their home at Bali Paradise Beach Estates
Prices are up to 70 % off Normal for the next few Months. Start at $8.00.
*Prices does not include 11% tax or electricity.
Limited Villas Book Now to Avoid Disappointment:
Interested parties please contact me, Lawrence, directly at 62-8123814014 Email: lbptbali@gmail.comOr our Rentals Manager: Yanthi at +62 815-5890-0389 or our Reception at PT Bali Luxury Villas at 62-361-284069
To share this information copy this link & send https://baliworldnewsviews.blogspot.com/2020/05/bali-reopening-to-tourists-everything.html
Bali Luxury Retirement Villas
Only 2.98 Milyar (* $184,888 U.S.D. or$268,888 Aus.)
Click here to see full video on Bali Luxury Retirement Villas.
1. INTRODUCTION
2. THE LOCATION
3. DESIGN & COSTS
4. PROFIT & INCOME
5. TERMS & CONDITIONS
6. BALI INFORMATION
7. RETIREMENT VISA
Features of © Bali Luxury Retirement Villas as low as * $184,888.
•100% legal for foreigners.• Includes leases totaling 80 yrs.
• Private carport included.
• Private 8 m (27 Ft.) pool** for leisurely laps.
• Only 200 Mtr. To a fabulous beach, restaurants, beach clubs.
• Great investment for you and your heirs.
• Private Housekeepers & drivers, only $200 MTh.
• Healthcare at a fraction of Western costs.
• Brand-new hospital within five minutes.
• Award-winning International Airport 35 min.
• Proximity to Sanur, Ubud, Denpasar.
• Walking distance to affordable restaurants and beach clubs
• Shared low costs of pool man and gardeners.
• Minuscule monthly common area fees.
• Managed by 15-year-old, Hall of Fame award-winning management company.
• *Price of the least expensive villa in U.S.D. after $10,000 Discount for the first two villas only. Subject to change without notice.
Developed and managed by 14-year-old Hall of Fame award-winning Bali company.
These villas offer you an opportunity to own a luxury home on arguably the Best Island in the world with some of the greatest weather, lowest cost of living, clean air, and friendliest people.
Profit Now Move in Later:
Limited Offer: Save $10,000:
As with any new project we are anxious to sell the first few villas.We have one already on hold and are only willing to offer one other villa at a $10,000 discount. First come first serve.
Free Stay in Luxury Estate:
Cheers, THE SALES TEAM © Bali Luxury Retirement Villas
PLEASE CALL OR EMAIL US: Tel: 62-361-284069 Mobile or Whatsapp 62-812-3814014 Email: infoBLRV@gmail.com
P.S. We also have several larger villas available from two-bedroom to four-bedroom starting as low as $158,888. www.baliluxuryvillasales.com
To share this information copy this link & send https://baliworldnewsviews.blogspot.com/2020/05/this-new-bali-based-swimwear-brand.html
Save $100,000 On Huge Estate
Only $488,888 Freehold or 80 year leases
Please contact us if you wish for further information. Tel: 62-361-284069 Mobile or Whatsapp 62-812-3814014 Email: infoBLRV@gmail.com
Free Bali Real Estate Seminar Video:
Whether you are a buyer, seller, broker, agent, investor, lessor or renter you can benefit from viewing PT. B.A.L.I’s latest Free Bali Real Estate Seminar Video filmed just a few months ago.
During this Free Bali Seminar Video you will learn about:
To share this information copy this link & send https://baliworldnewsviews.blogspot.com/2020/05/bali-reopening-to-tourists-everything.html
No comments:
Post a Comment